Please assess the completion status of the following clinical trial:

Trial Title: Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age~2. Has end stage renal disease (ESRD) and is to receive a kidney transplant from a living donor (LD) to whom he/she has either:~   1. A positive crossmatch requiring pretransplant desensitization (defined as a positive T-cell FCXM of greater than or equal to 300 but less than 450 prior to desensitization, or as a positive B-cell FCXM of \> 300 but \< 450 prior to desensitization with demonstrable Class II donor specific alloantibody (DSA) on solid-phase assays). Subsequent to desensitization, patient must have, at the time of transplant, a T-cell and B-cell FCXM less than 300; or~  2. A positive crossmatch not requiring desensitization (defined as FCXM between 200 and 299)~3. Willing to comply with the protocol~4. Females of child-bearing potential must have a negative pregnancy test (serum β-HCG) and sexually active females must agree to use a reliable and medically approved method of contraception~5. Willing and able to give written informed consent~6. Vaccinated against Neisseria meningitides (quadrivalent vaccine), Pneumococcus or H. influenzae at least two weeks prior to beginning desensitization~Exclusion Criteria:~1. Unstable cardiovascular condition~2. Previous splenectomy~3. Active bacterial or other infection which is clinically significant in the opinion of the investigator~4. Known or suspected hereditary complement deficiency~5. Participation in any other investigational drug study or was exposed to an investigational drug or device within 30 days of randomization~6. Pregnant, breast-feeding, or intending to conceive during the course of the study, including the two month follow-up period after drug discontinuation~7. Known hypersensitivity to the treatment drug or any of its excipients~8. History of illicit drug use or alcohol abuse within the previous year~9. History of meningococcal disease~10. Medical condition that, in the opinion of the investigator, might interfere with the patient's participation in the study, pose an added risk for the patient, or confound the assessment of the patient (e.g. severe cardiovascular or pulmonary disease)~11. Previously been enrolled in this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Patients received eculizumab intravenously according to details provided in the intervention description.

Based on this trial design, predict the completion outcome and termination type (if applicable).